Impact of COVID-19 Pandemic on Infection Prevention Professionals Explored
65 percent of respondents reported burnout; more negative mental health impacts seen for frontline and practicing IPs
CDC Report Addresses Impact of COVID-19 on Antimicrobial Resistance
Increases in resistant infections from 2019 to 2020 seen for carbapenem-resistant Acinetobacter, antifungal-resistant Candida auris
COVID-19 Incidence Not Increased With Corticosteroid Injections
Incidence of COVID-19 lower for adults receiving image-guided corticosteroid injections for pain management
Spike RBD IgG Antibodies Persist After SARS-CoV-2 Infection
Antibody levels higher for children versus adults across all follow-up time points up to 10 months after infection
Breakthrough Infections in Lupus Patients Down With COVID Booster
Sixty-four percent of those with breakthrough COVID-19 had received booster compared with 82 percent of those without breakthrough infection
NIH Trial Underway for Universal Flu Vaccine
Phase 1 trial testing both intranasal and intramuscular administration
Biden Administration May Back Second Booster Shots for All Adults
Expanding eligibility requirements for a fourth dose of the vaccine would require regulatory approval
Treatment for Hep C Up Among People Who Inject Drugs
Among PWID with chronic HCV infection, proportion with detectable HCV RNA decreased from 100 percent in 2006 to 48 percent in 2019
Infant Hospitalization for COVID-19 Reduced With Maternal Vaccination
Effectiveness of maternal vaccination against COVID-19 hospitalization in infants 80 percent during delta, 38 percent during omicron
New Omicron Subvariant Spreading in India, United States
New mutation -- BA.2.75 -- has been detected in 10 other countries, including Australia, Germany, the United Kingdom, and Canada
